EXCALIBUR PHARMACEUTICALS
Live / Registered — Registered (as of 24 Dec 2024)
What this means for you
Registered since 24 Dec 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88624847
- Registration number
- 7626610
- Mark type
- Stylized text
- Filed
- 20 Sept 2019
- Published for opposition
- 09 Feb 2021
- Registered
- 24 Dec 2024
- Attorney of record
- Christina M. Licursi
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical, therapeutic and biopharmaceutical agents for the treatment of fibrosis, cirrhosis, liver disease, kidney disease, dermatological conditions and diseases, autoimmune diseases, inflammatory diseases, Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis (NASH), and Capsular contracture; pharmaceutical, therapeutic and biopharmaceutical preparations and substances for the treatment of fibrosis, cirrhosis, liver disease, kidney disease, dermatological conditions and diseases, autoimmune diseases, inflammatory diseases, Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis (NASH), and Capsular contracture; none of the foregoing for or related to the treatment of male erectile dysfunction
Owner
- Excalibur Pharmaceuticals, Inc., New York, NY, US
- Excalibur Pharmaceuticals, Inc., New York, NY, US
- Excalibur Pharmaceuticals, Inc., New York, NY, US
Prosecution history
- 24 Dec 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 24 Dec 2024 — REGISTERED-PRINCIPAL REGISTER
- 05 Dec 2024 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 05 Dec 2024 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 04 Nov 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 04 Nov 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 04 Nov 2024 — ASSIGNED TO LIE
- 08 Aug 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 08 May 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 08 May 2024 — NON-FINAL ACTION E-MAILED
- 08 May 2024 — SU - NON-FINAL ACTION - WRITTEN
- 16 Apr 2024 — STATEMENT OF USE PROCESSING COMPLETE
- 08 Apr 2024 — USE AMENDMENT FILED
- 08 Apr 2024 — TEAS STATEMENT OF USE RECEIVED
- 06 Sept 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED